European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey

Authors

  • L. Dubertret,

    1. Service de Dermatologie, Hôpital Saint-Louis, 1 avenue Claude Vellefaux, 75475 Paris Cedex 10, France
      *Department of Dermatology, Venereology and Allergology, University Clinic Schleswig-Holstein, Kiel, Germany
      †Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland
      ‡Department of Dermatology, University Medical Centre Nijmegen, 6500 HB Nijmegen, The Netherlands
      §Department of Dermatology, Policlinico di Roma ‘Tor Vergata’, Rome, Italy
      ¶Department of Dermatology, University of Florence, Florence, Italy
      **Ob. Rebberg 22, Bad Säckingen, Germany
    Search for more papers by this author
  • U. Mrowietz,

    1. Service de Dermatologie, Hôpital Saint-Louis, 1 avenue Claude Vellefaux, 75475 Paris Cedex 10, France
      *Department of Dermatology, Venereology and Allergology, University Clinic Schleswig-Holstein, Kiel, Germany
      †Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland
      ‡Department of Dermatology, University Medical Centre Nijmegen, 6500 HB Nijmegen, The Netherlands
      §Department of Dermatology, Policlinico di Roma ‘Tor Vergata’, Rome, Italy
      ¶Department of Dermatology, University of Florence, Florence, Italy
      **Ob. Rebberg 22, Bad Säckingen, Germany
    Search for more papers by this author
  • A. Ranki,

    1. Service de Dermatologie, Hôpital Saint-Louis, 1 avenue Claude Vellefaux, 75475 Paris Cedex 10, France
      *Department of Dermatology, Venereology and Allergology, University Clinic Schleswig-Holstein, Kiel, Germany
      †Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland
      ‡Department of Dermatology, University Medical Centre Nijmegen, 6500 HB Nijmegen, The Netherlands
      §Department of Dermatology, Policlinico di Roma ‘Tor Vergata’, Rome, Italy
      ¶Department of Dermatology, University of Florence, Florence, Italy
      **Ob. Rebberg 22, Bad Säckingen, Germany
    Search for more papers by this author
  • P.C.M. Van De Kerkhof,

    1. Service de Dermatologie, Hôpital Saint-Louis, 1 avenue Claude Vellefaux, 75475 Paris Cedex 10, France
      *Department of Dermatology, Venereology and Allergology, University Clinic Schleswig-Holstein, Kiel, Germany
      †Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland
      ‡Department of Dermatology, University Medical Centre Nijmegen, 6500 HB Nijmegen, The Netherlands
      §Department of Dermatology, Policlinico di Roma ‘Tor Vergata’, Rome, Italy
      ¶Department of Dermatology, University of Florence, Florence, Italy
      **Ob. Rebberg 22, Bad Säckingen, Germany
    Search for more papers by this author
  • S. Chimenti,

    1. Service de Dermatologie, Hôpital Saint-Louis, 1 avenue Claude Vellefaux, 75475 Paris Cedex 10, France
      *Department of Dermatology, Venereology and Allergology, University Clinic Schleswig-Holstein, Kiel, Germany
      †Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland
      ‡Department of Dermatology, University Medical Centre Nijmegen, 6500 HB Nijmegen, The Netherlands
      §Department of Dermatology, Policlinico di Roma ‘Tor Vergata’, Rome, Italy
      ¶Department of Dermatology, University of Florence, Florence, Italy
      **Ob. Rebberg 22, Bad Säckingen, Germany
    Search for more papers by this author
  • T. Lotti,

    1. Service de Dermatologie, Hôpital Saint-Louis, 1 avenue Claude Vellefaux, 75475 Paris Cedex 10, France
      *Department of Dermatology, Venereology and Allergology, University Clinic Schleswig-Holstein, Kiel, Germany
      †Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland
      ‡Department of Dermatology, University Medical Centre Nijmegen, 6500 HB Nijmegen, The Netherlands
      §Department of Dermatology, Policlinico di Roma ‘Tor Vergata’, Rome, Italy
      ¶Department of Dermatology, University of Florence, Florence, Italy
      **Ob. Rebberg 22, Bad Säckingen, Germany
    Search for more papers by this author
  • G. Schäfer,

    1. Service de Dermatologie, Hôpital Saint-Louis, 1 avenue Claude Vellefaux, 75475 Paris Cedex 10, France
      *Department of Dermatology, Venereology and Allergology, University Clinic Schleswig-Holstein, Kiel, Germany
      †Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland
      ‡Department of Dermatology, University Medical Centre Nijmegen, 6500 HB Nijmegen, The Netherlands
      §Department of Dermatology, Policlinico di Roma ‘Tor Vergata’, Rome, Italy
      ¶Department of Dermatology, University of Florence, Florence, Italy
      **Ob. Rebberg 22, Bad Säckingen, Germany
    Search for more papers by this author
  • EUROPSO patient survey

    1. Service de Dermatologie, Hôpital Saint-Louis, 1 avenue Claude Vellefaux, 75475 Paris Cedex 10, France
      *Department of Dermatology, Venereology and Allergology, University Clinic Schleswig-Holstein, Kiel, Germany
      †Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland
      ‡Department of Dermatology, University Medical Centre Nijmegen, 6500 HB Nijmegen, The Netherlands
      §Department of Dermatology, Policlinico di Roma ‘Tor Vergata’, Rome, Italy
      ¶Department of Dermatology, University of Florence, Florence, Italy
      **Ob. Rebberg 22, Bad Säckingen, Germany
    Search for more papers by this author

  • Conflicts of interest None declared.

L. Dubertret.
E-mail: louis.dubertret@free.fr

Summary

Background  EUROPSO (European Federation of Psoriasis Patient Associations) undertook a Europe-wide survey examining quality of life and patients’ perspectives on treatment and their disease.

Objectives  To explore patients’ perspectives of psoriasis on their lifestyle and well-being and to gain insight into the effectiveness of and satisfaction with currently available therapies for psoriasis.

Methods  Self-administered questionnaires (n = 50 500) were mailed to members of psoriasis patient associations in Belgium, the Czech Republic, Finland, France, Germany, Italy and the Netherlands.

Results  Responses were received from 18 386 patients (36%), of whom 17 990 had psoriasis. Mean age at onset of psoriasis was 30·5 years, 59% of respondents had self-reported moderate to severe psoriasis (3% or greater body surface area involvement) and 30% had been diagnosed with psoriatic arthritis. The mean Psoriasis Disability Index score was 12·2 (25% of the maximum score), increasing to 21 (44%) in patients with more than 10% body surface area involvement. The greatest impact was on activities of daily living, especially affecting clothing choice, bathing routine and sporting activities. Overall, 77% replied that psoriasis was a problem or a significant problem. While patients were satisfied with the information and care from their dermatologist (40% highly satisfied), available treatment options were less satisfactory, with over 70% reporting only low to moderate satisfaction.

Conclusions  This is the largest survey of people with psoriasis in Europe and shows that psoriasis has a profound impact on quality of life.

Ancillary